Average Co-Inventor Count = 4.58
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Rorer Pharmaceutical Corporation (8 from 109 patents)
2. Rhone-poulenc Rorer Pharmaceuticals Inc. (7 from 111 patents)
3. Dupont Pharmaceuticals Company (4 from 106 patents)
4. Other (2 from 832,680 patents)
5. Janssen Pharmaceutica Nv (2 from 2,076 patents)
6. Bristol-myers Squibb Pharma Company (2 from 234 patents)
7. Bristol-myers Squibb Compnay (1 from 3,681 patents)
8. The Dupont Merck Pharmaceutical Company (1 from 206 patents)
27 patents:
1. 7795440 - N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
2. 7196110 - N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
3. 6602895 - Inhibitors of factor Xa with a neutral P1 specificity group
4. 6602871 - Thrombin or factor Xa inhibitors
5. 6548525 - Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors
6. 6403620 - Inhibitors of factor Xa with a neutral P1 specificity group
7. 6403583 - Thrombin or factor Xa inhibitors
8. 6271237 - Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
9. 6060462 - Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
10. 5998424 - Inhibitors of factor Xa with a neutral P1 specificity group
11. 5939418 - Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
12. 5925635 - N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
13. 5468898 - Substituted naphthylene compounds exhibiting selective leukotriene
14. 5232948 - Substituted monocyclic aryl compounds exhibiting selective leukotriene
15. 5210208 - Disubstituted aryl compounds exhibiting selective leukotriene B4